Company intelligence / Profile preview

Medicem International

Ownership: Private
Employees: ~84
Development stage: Other

Overview

Medicem’s flagship product Dilapan-S®—a synthetic osmotic hygroscopic cervical dilator—has global regulatory approvals including the USA and Europe. It provides a non-pharmacologic option for predictable and reliable cervical ripening. The company has developed over a dozen products based on its proprietary hydrogel platform across gynecology, ophthalmology, dermatology, wound care and surgery.

Therapeutic areas: DermatologyOphthalmologyWomen's HealthOther
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Partnerships

International network of distributors

Beyond the preview

Go deeper on Medicem International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medicem International.

Explore the full profile